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ABSTRACT 
The main aim to improve the systemic bioavailability of Ramipril by the design of transdermal drug delivery based on chitosan 
nanoparticles dispersed into gels. When chitosan nanoparticles dispersed into gels consisting of poloxamer and carbopol the resulting 
formulation exhibited thixotropic behavior with a prolonged drug release properties. Our study demonstrated that the designed 
nanoparticles gel transdermal delivery system has a potential to improve the systemic bioavailability and the therapeutic efficacy of 
Ramipril loaded chitosan nanoparticles dispersed in carbopol gels. There is no incompatibility between drug and polymers by 
performing FTIR and DSC. To characterize the rate controlling membrane of transdermal patches. The thickness ranged between 
TNPGF1 to F9 0.11 ± 0.05 mm to 0.19 ± 0.07 mm, which indicates that they are uniform in thickness. The different batches of 
formulations weights variations were relatively good uniformity of weight variations among the various batches was observed, with 
all formulations and ranged from 1.40 ± 1.2% to 1.78 ± 2.0%. The flatness study showed that all the formulations had the same strip 
length before and after their cuts, indicating 99% flatness. The tensile strength of the TNPGF1 to TNPGF9 shows the 10.14 ± 1.19 to 
12.78 ± 2.45 shows the excellent viscosity. The total amount of drug is present in the transdermal patches of TNPGF1 to TNPGF9 
was found to be 90.5 ± 0.3 % to 98.5 ± 0.1 %. In-vitro Franz’s diffusion drug Release Studies of among all formulations best 
formulation TNPGF6. The drug release through the transdermal patches of Ramipril, follows first order kinetics with diffusion 
controlled mechanism. 
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INTRODUCTION 
Transdermal drug delivery system: At present, the most 
common form of delivery of drugs is the oral route. While 
this has the notable advantage of easy administration, it 
also has significant drawbacks namely poor ability due to 
hepatic metabolism (first pass) and the tendency to produce 
rapid blood level spikes (both high and low), leading to a 
need for high and/or frequent dosing, which can be both 
cost prohibitive and inconvenient 
1
. 
Advantages  
1. Transdermal drug delivery can be used as an 
alternative delivery system for patients who cannot 
tolerate oral dosage forms.  
2. Avoid the first pass effect e.g. transdermal 
nitroglycerin. It is rapidly metabolized by the liver 
when taken orally 
2
.  
3. Drug therapy may be terminated rapidly by removal of 
the application from the surface of the skin.  
4. It is of great advantage in patients who are nauseated 
or unconscious.  
5. Allows continued drug administration permitting the 
use of a drug with short biological half-life. 
Disadvantages 
1. The drug, the adhesive or other excipients in the patch 
formulation can cause erythema, itching, and local 
edema.  
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2. The barrier function of the skin changes from one 
site to another on the same person, from person to 
person and also with age 
3
.  
3. Some drugs e.g. scopolamine transdermal patch 
placed behind the ear, it is uncomfortable.  
4. Adhesion may vary with patch type and 
environmental conditions.  
5. Drugs that require high blood levels cannot be 
administered.  
MATERIALS AND METHODS 
The pure drug of Ramipril was obtained from Hetero 
drug Limited, Hyderabad and excipiens like Chitosan, 
Poloxamer, HPMC, Pentasodium tripolyphosphate, 
Dimethyl sulfoxide, Carbopol, Acetic acid, dimethyl 
sulfoxide obtained from Pharmaceutical Pvt Ltd, Navi 
Mumbai. 
Formulation of Ramipril Loaded chitosan 
nanoparticles dispersed in carbopol gel: 
Preparation of Nanoparticles:  
Nanoparticles were  Prepared by the  ionic gelation 
technique at  room  temperature  with  combinations  of  
different ratio of chitosan as shown in table and  
Pentasoidum tripoly phosphate. Chitosan was dissolved 
in acetic acid solution adjusted to pH 4.5 and TPP was 
dissolved in Milli-Q water (The system monitors the ion 
concentration by measuring the electrical resistivity of 
the water). TPP  solution  was  added drop wise  to an  
equal  volume  of  chitosan  solution  under  magnetic 
stirring  at 650  rpm   over  60  min.   Ramipril loaded  
chitosan  nanoparticles  were prepared  by the  same  
method  mentioned  above, but  that  the  appropriate 
amount  of  Ramipril was  dissolved  in  chitosan  
solution  before  the  dropwise addition  of  TPP  
solution 
4
.  
Formulation of gels:   
Poloxamer gels were prepared by using the cold 
technique. Poloxamer  was  slowly  added into certain  
volume  of  cold Milli Q  water (5-10 
o
C)  with constant  
stirring  for 60 min at 650  rpm. Additional  amount  Of 
Cold Milli-Q water was added   to the  solution   at  30 
min  to  make  up  to  the  volume 
5
.  Poloxamer  
solutions were  kept  in  the  refrigerator  (4-5 
o
C) over 
night  then  kept  at room temperature  for   a  further  24 
h  Carbopol  940 (1%  and  2 %  w/v)  gels  were  
prepared   by   dispersing appropriate  amount  of  
carbopol  into  certain volume  of  Milli-Q water  At  
room  temperature  with  constant  stirring   for  60  min  
at 650  rpm. Milli-Q water  was  added  to  the  solution  
at  30  min  to Make  up  the  volume   to  the  total  
amount.  Carbopol gels were kept at room temperature 
for 24 h. Poloxamer and carbopol combination gels were 
prepared with similar methods as above. Both were 
stirred at 650 rpm for 60 min 
6
. At  30  min,  the  two  
were  mixed  and  Milli Q Water  was  added  to  the  
mixture  with  stirring  to  make  up  the volumes  to the 
total  amount. These gels were kept at room temperature 
for 24h.  
Formulation of nanoparticles / gels transdermal 
delivery Systems:  
The prepared Ramipil loaded chitosan naoparticles 
dispersed in carbopol gels incorporated in transdermal 
molds and the characteristics of resultant transdermal 
delivery systems was evaluated 
7
. 
 
Table 1: Formulation design of Transdermal Patches of Ramipril Loaded chitosan nanoparticles dispersed in carbopol 
gels TNPGF1 to TNPGF5 
Ingredients TNPGF1 TNPGF2 TNPGF3 TNPGF4 TNPGF5 
Ramipril (gms) 1 1 1 1 1 
Chitosan (gms) 2 2 2 2.5 2 
Polaxamer (gms) 5 5 5 4 4 
HPMC (gms) 2 1 0.5 1 1 
Pentasodium tripolyphosphate (gms) 0.5 0.5 0.5 0.5 0.5 
Dimethyl sulfoxide (ml) 1 1 1 1 1 
Carbopol (gms) 2 2 2 2 2 
Acetic acid (ml)  15 15 15 15 15 
 
Table 2: Formulation design of Transdermal Patches of Ramipril loaded chitosan nanoparticles dispersed in carbopol 
gels TNPGF6 to TNPGF9 
Chemical name  TNPGF6 TNPGF7 TNPGF8 TNPGF9 
Ramipril (gms) 1 1 1 1 
Chitosan (gms) 3 1 1 1 
Polaxamer (gms) 4 3 3 3 
HPMC (gms) 1 1.5 1.5 1.5 
Pentasodium tripolyphosphate (gms) 0.5 0.5 0.5 0.5 
Dimethyl sulfoxide (ml) 1 1 1 1 
Carbopol (gms) 2 2 2 2 
Acetic acid (ml) 15 15 15 15 
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Evaluation studies: 
Drug-Polymer Compatibility studies 
FT-IR Spectra: Prior to the development of the dosage 
forms, infrared spectra of the physical mixture of the 
Ramipril, polymers individually and the mixture of drug 
and polymer were taken. The drug-Polymer Interaction 
were studied by FTIR spectrometer, shimadzu 8400S 
2% w/w of the sample with respect to a potassium 
Bromide mixed with drug KBr 
8
.  
Differential scanning calorimetry: The output of a 
DSC is a plot of heat flux (rate) versus temperature 
at a specified temperature rate 
9
. DSC provides 
information about the physical properties of the 
sample as crystalline or amorphous nature and 
demonstrates a possible interaction between drug 
and polymers in formulations.  
Physicochemical evaluation of films: 
Thickness of the Patch: The thickness of patches was 
measured at three different places using a micrometer 
(Mitutoyo Co., Japan) and mean values were calculated 
10
. 
Weight Variation: The patches were subjected to mass 
variation by individually weighing randomly selected 
patches 
11
. Such determination was carried out for each 
formulation. 
Moisture Content: The patches (n =3) were weighed 
individually and kept in a desiccator containing calcium 
chloride at 37 °C for 24 hrs. The final weight was noted 
when there was no change in the weight of individual 
patch 
12
. The percentage of moisture content was 
calculated as a difference between initial and final 
weight with respect to final weight.  
Moisture Uptake: A weighed film kept in desiccators at 
40 °C for 24h was taken out and exposed to two 
different relative humidity of 75% RH (saturated 
solution of sodium chloride) and 93% RH (saturated 
solution of ammonium hydrogen phosphate) in two 
different desiccators respectively at room temperature 
then the weights were measured periodically to constant 
weights 
13
. 
Flatness: Longitudinal strips were cut out from the 
prepared medicated film the lengths of each strip were 
measured. Then variation in the length due to the non-
uniformity in flatness was measured 
14
. Flatness was 
calculated by measuring constriction of strips and a zero 
percent constriction was considered to be equal to a 
hundred percent flatness.  
Constriction (%) =
     
  
× 100 
Where, 
L1- initial length of strip 
L2 - final length of strip. 
Determination of Tensile Strength: In order to 
determine the elongation as a tensile strength, the 
polymeric patch was pulled by means of a pulley system 
weights were gradually added to the pan to increase the 
pulling force till the patch was broken 
15
. The elongation 
i.e. the distance traveled by the pointer before break of 
the patch was noted with the help of magnifying glass on 
the graph paper, the tensile strength was calculated as kg 
cm
2
. 
Folding Endurance: This was determined by repeatedly 
folding one film at the same place till it broke. The 
Timber of times the film could be folded at the same 
place without breaking gave the value of folding 
endurance 
16
. 
Water Vapour Transmission (WVT) Rate: WVTR is 
defined as the quantity of moisture transmitted through 
unit area of film in unit time. The film was fixed over 
the brim of a glass vial, containing 3 g of fused calcium 
chloride as desiccant, with an adhesive tape 
76
. The vial 
was weighed and kept in desiccators containing 
saturated solution of potassium chloride to provide 
relative humidity of 84%. The vial was taken out and 
weighed at every 24 hrs interval for a period of 72 hrs 
17
. 
The water vapour transmission rate was calculated from 
the plots of amount of water vapour transmitted versus 
time. 
Drug Content Determination: The patches at 1cm2 
were cut and added to a beaker containing 100ml of 
Phosphate buffered solution of pH 7.4. The medium was 
stirred with a Teflon coated magnetic bead for 5hrs 
18
. 
The solution was later filtered and analyzed for drug 
content with proper dilution at 219 nm 
spectrophotometrically. 
In vitro Franz’s diffusion studies of Transdermal 
patches of Ramipril though chitosan nanoparticles 
dispersed in carbopol gels: In vitro release studies can 
be performed in a modified Franz diffusion cell over a 
period of time 12 hours. At specific time intervals, 
aliquots of samples containing the released drug are 
taken from the acceptor compartment and are quantified 
using a suitable method 
19
. The fabricated film was 
placed on the rat skin and attached to the diffusion cell 
such that the cell’s drug releasing surface towards the 
receptor compartment which was filled with phosphate 
buffer solution of pH 7.4 at 37±1 °C. The elution 
medium was stirred magnetically. The aliquots (5ml) 
were withdrawn at predetermined time intervals and 
replaced with same volume of phosphate buffer of pH 
7.4. The samples were analyzed for drug content using 
UV spectrophotometer at 219 nm. 
Mathematical modeling of release kinetics 
20
: The in 
vitro drug release data were fitted to various release 
kinetic models namely first order (Ln Qo- k1 t), 
zeroorder Q= (Qo_ko t), Higuchi equations (Q=kh 2)1/2, 
Korsemeyer-Peppas (logQtvs log t),  
Where 
Qt, is the cumulative amount of drug released at time t 
and 
 Q0 is the initial amount of drug present in Microspheres. 
Ko is the zero order release rate constant, k1 is the first 
order release rate constant, and kh is the diffusion rate 
constant.
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RESULTS AND DISCUSSION 
Compatability Studies: 
 
Figure 1: FTIR Spectra of Ramipril (pure drug) 
 
Figure 2: FTIR Spectra of TPP 
 
Figure 3: FTIR Spectra of Carbopol 
 
Figure 4: FTIR Spectra of Poloxamer 
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Figure 5: FTIR Spectra of chitosan 
 
Figure 6: FTIR Spectra of HPMC 
 
Figure 7: FTIR Spectra of Mixtures 
 
Table 3: FTIR spectrum of observed and characteristic peak of Drug, Excipients & Mixture of compounds 
FTIR 
Spectrum  
IR absorption bands (cm-1) Bond  Functional group 
Observed peak Characteri
stic peak 
 
 
 
Ramipril 
3678.49,3616.39,3562.90,3453.48,3384.85. 3000-3700 O-H stretch Alkenes, aromatic 
2907.11,2761.87,2720.98. 2500-3000 C-H stretch Alkenes, aromatic ring 
2558.16,2360.72,2303.70. 2100-2660 C=C stretch Alkynes  
1707.13,1644.98,1462.75, 
1422.30,1346.05. 
600-1500 C-Cl  stretch Alkenes  
TPP 3623.09,3448.80,3410.81,3352.62,3309.14, 3000-3700 O-H stretch Alkenes, aromatic 
 2893.37, 90.15 
 2816.21, 92.9 
 3448.89, 78.99 
 3560.77, 82.81 
 1639.57, 91.3 
 2225.96, 104.5 
 3217.42, 84.03 
 3583.92, 85.54 
 3618.64, 88.44 
 3846.25, 101.3 
 3726.66, 103.8 
 1080.19, 84.88 
 991.46, 87.21 
 898.87, 92.35 
100015002000250030003500
80
85
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95
100
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110
 794.71, 0.7032 
 1084.05, 0.5175 
 1377.24, 0.5401 
 1666.58, 0.5311 
 1955.92, 0.7319 
 2249.11, 0.6838 
 2538.45, 0.6283 
 2831.64, 0.5075 
 3128.69, 0.4544 
 3414.17, 0.6106 
 3707.37, 0.5283 
 3996.70, 0.5155 
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3215.31,3150.70 3100-3330 N-H strceh Aromatic ring 
2978.58,2871.58,2818.31,2700.81,2598.57,2546
.08 
2500-3000 C-H stretch Alkenes ,aromatic ring 
2498.65,2393.58,2281.52,2212.79 2100-2660 C=C stretch alkynes 
Carbopol 3647.52,3617.85,3540.03,3473.00,3170.27,3035
.53 
3000-3700 O-H strech Alkenes,aromaric 
2967.04,2869.43,2725.17,2663.71,2554.60 2500-3000 C-H strech  Alkenes,aromaric ring 
1493.80,1046.32,983.94,906.69,840.89,789.55,7
43.58,653.06 
600-1500 C-Cal strech Alkanes  
Poloxamer 3693.53,3647.88,3557.92,3298.14,3064.94 3000-3700 O-H stretch Alkenes,aromaric 
2869.82,2656.26,2615.79,2518.11, 2500-3000 C-H stretch Alkenes, aromaric ring 
1466.79,1386.21,1265.72,1161.59,1078.20,1009
.19,947.51,890.80,831.46,776.94,729.64,686.63,
645.20 
600-1500 C-Cl stretch Alkenes  
Chitosan 3618.64,3583.92,3448.89,3560.77 3000-3700 O-H stretch Alkenes, aromatic 
3217.42 3010-3300 N-H stretch aromatic 
2893.37,2225.96, 2850-2960 C-H stretch alkanes 
1639.57 1600-1900 C=O stretch Aldehydes, ketones,  
HPMC 794.71 600-1500 C-Cl stretch Alkenes 
1084.05 1000-1300 C-O stretch Alcohols, ethers 
1666.58 1660-1580 C=O stretch Alkenes 
2249.11,2538.45 2100-2660 C=C stretch Alkynes 
Mixture of 
compounds 
3682.31,3615.57,3501.41, 
3447.12,3154.37,3110.11 
3000-3700 O-H stretch Alkenes, aromatic. 
2718.03  C-H stretch Alkenes, aromatic ring  
2355.95,2325.47,2144.86, 
2043.75 
2100-2660 C=C stretch Alkynes 
1739.71,1693.58 1680-1760 >C=O Aldehydes, ketones. 
 
DSC spectra: 
 
Figure 8: DSC Spectrum of Ramipril 
 
Figure 9: DSC Spectrum of Chitosan 
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Figure 10:   DSC Spectrum of HPMC 
 
Figure 11: DSC Spectrum of Carbopol 
 
Figure 12: DSC Spectrum of Poloxamer 
 
Figure 13: DSC Spectrum of TPP 
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Figure 14: DSC Spectrum of Mixtures 
Table 4: DSC Spectrum of ramipril, Excipients & Mixtures  
SI.No Ingredients Endothermic peak Exothermic peak 
1 Ramipril 2.8515 J/g & 277.59
o
C -- 
2 Chitosan 223.91
 o
C 55.35
 o
C 
3 Hydroxyl propyl methyl cellulose 224.70
 o
C &215.23
 o
C -- 
4 Carbopol 52.96 
o
C/157.5 J/g 20.22
 o
C/201.3 J/g 
5 Poloxamer 54.23
 o
C/339.3 J/g 223.91
 o
C/350.2 J/g 
6 TPP(Pentasodium tripolyphosphate) 53.17 
o
C/134.9 J/g 220.1 
o
C 
7 Mixtures 229.24
 o
C/201.3 J/g 50.34
 o
C/157.78J/g 
 
Evaluation of ramipril transdermal patchs 
Physicochemical Evaluation of Films  
Thickness of the Patch: The thickness ranged between 
0.11 ± 0.05 mm to 0.19 ± 0.07 mm, which indicates that 
they are uniform in thickness as shown in the Table 5. 
Weight Variation: The different batches of 
formulations weights variations were relatively good 
uniformity of weight variations among the various 
batches was observed, with all formulations and ranged 
from 1.40 ± 1.2% to 1.78 ± 2.0%. The results indicate 
that the process employed to prepare patches in this 
study was capable of producing patches with uniform 
drug content and minimal patch variability. As shown in 
the Table 5. 
Moisture Uptake: Moisture content and moisture 
uptake studies indicated that the increase in the 
concentration of hydrophilic polymer was directly 
proportional to the increase in moisture content and 
moisture uptake of the patches. The moisture content of 
the prepared formulations was low, which could help the 
formulations remain stable and reduce brittleness during 
long term storage. The moisture uptake of the 
formulations was also low, which could protect the 
formulations from microbial contamination and reduces 
bulkiness. As shown in the Table 5. 
Flatness: The flatness study showed that all the 
formulations had the same strip length before and after 
their cuts, indicating 99% flatness. Thus, no amount of 
constriction was observed; all patches had a smooth, flat 
surface; and that smooth surface could be maintained 
when the patch was applied to the skin. As shown in the 
Table 5. 
Determination of Tensile Strength: The Tensile 
strength of the TNPGF1 to TNPGF9 shows the 10.14 ± 
1.19 to 12.78 ± 2.45 shows the excellent viscosity. As 
shown in the Table 5. 
Folding Endurance: Folding endurance test results 
indicated that the patches would not break and would 
maintain their integrity with general skin folding when 
applied. As shown in the Table 5. 
Water Vapour Transmission (WVT) Rate:  The 
WVTR was found to be TNPGF1 to TNPGF9 4.87 ± 
0.45 to 1.23 ± 0.21. As shown in the table 5. 
Drug Content Determination: The total amount of 
drug is present in the transdermal patches of TNPGF1 to 
TNPGF9 was found to be 90.5 ± 0.3 % to 98.5 ± 0.1 %. 
As shown in the table 5. 
In vitro release drug diffusion studies were 
performed using modified Franz diffusion cell 
In vitro release studies can be performed in a modified 
Franz diffusion cell over a period of time 5 hours. At 
specific time intervals, aliquots of samples containing 
the released drug are taken from the acceptor 
compartment and are quantified using a suitable method 
of determination Such as UV VISIB spectroscopy 
Ramipril = גּ max 219. The sink condition is usually 
maintained by replacing the volume of aliquots taken by 
similar volumes of the buffer to resemble constant 
clearance of drugs from their physiological site of 
action. The drug release parameters as shown in table 6. 
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Table 5: Physicochemical Evaluations of Films 
 TNPG1 TNPG2 TNPG3 TNPG4 TNPG5 TNPG6 TNPG7 TNPG8 TNPG9 
thickness 0.11± 
0.03 
0.12± 
0.05 
0.13± 
0.04 
0.15± 
0.06 
0.14± 
0.01 
0.18± 
0.01 
0.11± 
0.05 
0.13± 
0.02 
0.19± 
0.07 
Weight 
variation 
1.65± 
1.5 
1.78± 
2.0 
1.61± 
1.0 
1.65± 
1.5 
1.22± 
2.5 
1.40± 
1.2 
1.55± 
0.5 
1.65± 
1.5 
1.65± 
1.5 
Moisture 
uptake 
3.105± 
0.15 
2.125± 
0.25 
3.135± 
0.35 
2.145± 
0.25 
3.155± 
0.45 
4.24± 
0.23 
2.135± 
0.15 
3.145± 
0.35 
1.123± 
0.65 
Flatness% 95% 94% 96% 95% 98% 99% 98% 96% 95% 
Tensile 
strength(psi) 
11.11± 
1.11 
10.14± 
1.19 
11.12± 
2.12 
11.11± 
1.18 
12.11± 
2.01 
11.12± 
2.00 
12.78± 
2.45 
2.56± 
2.67 
11.76± 
2.12 
Folding 
endurance  
130.1±0.2
2 
120.5±3.
20 
164.2±2.
00 
240.1±3.
10 
150.2±2.
10 
199± 
1.00 
210.2±2
.10 
310.2±3.2
0 
206± 
3.10 
Water vapour 
transmission 
3.67± 
0.22 
2.68± 
0.12 
4.67± 
0.24 
1.23± 
0.21 
2.12± 
0.42 
3.00± 
0.22 
2.12± 
0.12 
3.80± 
0.23 
4.87± 
0.45 
Drug content  95.1± 
0.2 
93.7± 
0.4 
90.5± 
0.3 
91.5± 
0.2 
92.2± 
0.4 
98.5± 
0.1 
93.1± 
0.2 
94.2± 
0.3 
88.2±0.2 
 
 
 
Figure 15:  Cumulative % amount of drug release of Transdermal patch of Ramipril loaded chitosan 
nanoparticles dispersed in carobopol gels TNPGF1 to TNPGF9 
Table 6: Release order kinetics of Transdermal patch of Ramipril loaded chitosan nanoparticles dispersed in 
carobopol gels TNPGF1 to TNPGF9 
F. Code  Zero order First order Higuchi Korse meyer pappas 
R
2 
M R
2 
M R
2 
M R
2 
M 
TNPG1 0.973 10 0.596 0.024 0.958 98.73 0.951 1.526 
TNPG2 0.952 9.821 0.692 0.026 0.902 95.12 0.983 1.558 
TNPG3 0.949 10.47 0.643 0.025 0.935 103.6 0.964 1.539 
TNPG4 0.939 9.940 0.706 0.025 0.814 92.11 0.963 1.490 
TNPG5 0.973 11.13 0.771 0.027 0.812 101.1 0.12 0.005 
TNPG6 0.986 11.66 0.785 0.029 0.858 108.3 0.995 1.56 
TNPG7 0.951 29.10 0.699 0.032 0.920 284.9 0.979 1.789 
TNPG8 0.955 12.32 0.790 0.029 0.820 113.6 0.993 1.584 
TNPG9 0.988 10.41 0.749 0.028 0.919 99.97 0.985 1.538 
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CONCLUSION 
The present work showed that transdermal delivery 
system for ramipril based on chitosan nanoparticles 
dispersed into gel was successfully prepared and 
characterized. There is no Incompatibility between drug 
and polymers by performing FTIR and DSC. To 
characterize the rate controlling membrane of 
transdermal patches. The thickness ranged between 
TNPGF1 to F9 0.11 ± 0.05 mm to 0.19 ± 0.07 mm, 
which indicates that they are uniform in thickness. The 
different batches of formulations weights variations 
were relatively good uniformity of weight variations 
among the various batches was observed, with all 
formulations and ranged from 1.40 ± 1.2% to 1.78 ± 
2.0%. The flatness study showed that all the 
formulations had the same strip length before and after 
their cuts, indicating 99% flatness. The Tensile strength 
of the TNPGF1 to TNPGF9 shows the 10.14 ± 1.19 to 
12.78 ± 2.45 shows the excellent viscosity. The total 
amount of drug is present in the transdermal patches of 
TNPGF1 to TNPGF9 was found to be 90.5 ± 0.3 % to 
98.5 ± 0.1 %. In-vitro Franz’s diffusion drug Release 
Studies among all formulations the best formulation was 
TNPGF6.  The drug release through the transdermal 
patches of Ramipril follows First order kinetics with 
diffusion controlled mechanism. Effect of penetration 
enhancer like dimethyl sulfoxide has been checked on 
in-vitro permeation of drug and was found to be 
effective. Gels may create a drug reservoir to provide the 
system with ramipril over long period of time to control 
the blood pressure. 
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